MedTrace Logo

Real-World Study of Ceftazidime Avibactam in China

NCT05487586 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2025-09-04

Study results available
· View outcomes & findings →

Summary

This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.

Conditions

  • Hospital Acquired Pneumonia
  • Ventilator Acquired Pneumonia
  • Complicated Intra Abdominal Infections

Interventions

DRUG

ceftazidime avibactam group

Non-Interventional Study

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2024-07-11
Completion
2024-07-11
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05487586 on ClinicalTrials.gov